US FDA inspection at Unit-VI concluded with three procedural observations

Capex & Operations View source PDF Explain this filing

AUROPHARMA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+3.9%Reaction day

₹1652.00

prior close

₹1648.60

announcement price

After-mkt

timing

Nifty Midcap 150market+0.1%+3.8% vs market

Pharmaceuticals peers, median of 174sector-0.3%+4.2% vs sector

On the reaction day the stock moved 3.8 pts more than Nifty Midcap 150 and 4.2 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.3

10m

-0.2

15m

-0.4

30m

-0.3

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+3.9+0.1+3.8-0.3+4.2

Next day

+1.6-1.1+2.7-0.7+2.3

+1.4-1.7+3.1-0.5+1.8

-1.3-1.2-0.1-0.2-1.1

+0.0-1.4+1.4-0.1+0.1

+0.4-1.9+2.3+0.0+0.4

+2.8-2.2+5.0+0.0+2.8

15d

+2.8-3.1+5.8+0.0+2.7

+1.2-7.0+8.2-0.2+1.4

—————

UpDownMarket · Nifty Midcap 150Sector · Pharmaceuticals peers, median of 174Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

US FDA inspected Unit-VI, an API manufacturing facility of wholly owned subsidiary Apitoria Pharma Private Limited in Andhra Pradesh, from August 24 to 28, 2026. The inspection concluded with three observations, all described as procedural in nature. The company will respond to the US FDA within the stipulated timeline and reaffirmed its commitment to quality and compliance.

Likely market impact

Mildly positive as only procedural observations were noted. No major compliance flags, though FDA response is still pending.